Praveen Mehrotra is a Cardiology physician affiliated with Thomas Jefferson University. OpenAlex indexes 75 publications with 1,039 citations (h-index 16); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
925 Chestnut St
Mezzanine
Philadelphia, PA 191074216
Telephone
215-955-5050Registry record last updated 9 Nov 2012.
Clinical trials
- Study for the Assessment of the Quality of Echocardiographic Clips.
Sponsor: UltraSight
- Optimization of an Automated Ultrasound Cardiac Guidance Tool
Sponsor: UltraSight
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202520 payments
- Medtronic, Inc.Program year202510 payments
- GE HEALTHCAREProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
91%Statin22%Atorvastatin Calcium81%Rosuvastatin Calcium19%Part D≥59 patientsBeta blocker19.9%Metoprolol Succinate50%Carvedilol45%Atenolol5%Part D<11 patients+ 12 more classes in this area
Blood & clotting
9%Factor Xa inhibitor6.1%Eliquis81%Xarelto19%Part D<11 patientsP2Y12 inhibitor2.9%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluation of Intracardiac Pressures Using Subharmonic-aided Pressure Estimation with Sonazoid Microbubbles
Radiology Cardiothoracic Imaging
2024 - Noninvasive Evaluation of Cardiac Chamber Pressures Using Subharmonic-Aided Pressure Estimation With Definity Microbubbles
JACC. Cardiovascular imaging
2022 - Comparing Central Aortic Pressures Obtained Using a SphygmoCor Device to Pressures Obtained Using a Pressure Catheter
American Journal of Hypertension
2022
Similar KOLs
Other experts from the same institution or the same specialty.
David Whellan, MD
Thomas Jefferson University
Jesse Roman, MD
Thomas Jefferson University
Stephen Silberstein, MD
Thomas Jefferson University
David Cognetti, MD
Thomas Jefferson University
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”